Please check your internet connection and try again.
Pantoprazole is a proton pump inhibitor (PPI) used to decrease stomach acid production.
## Primary Indications
* Gastroesophageal reflux disease (GERD) symptomatic treatment
* Erosive esophagitis healing and maintenance
* Zollinger-Ellison syndrome and other hypersecretory conditions
* Peptic ulcer disease (PUD) treatment, often in combination with antibiotics for *H. pylori* eradication
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. May be increased to 80 mg once daily for short-term management of severe erosive esophagitis.
* **Hypersecretory Conditions:** 40 mg orally or intravenously once daily, increased as needed. Usual dose range 40-80 mg daily, divided doses may be required. Maximum dose typically 80 mg IV daily or 96 mg IV every 12 hours (divided doses).
* ***H. pylori* Eradication (Triple Therapy):** 40 mg orally twice daily for 7-14 days, in combination with amoxicillin 1000 mg orally twice daily and clarithromycin 500 mg orally twice daily. Or, 40 mg orally twice daily for 7-14 days, in combination with clarithromycin 500 mg orally twice daily and metronidazole 500 mg orally twice daily. Alternative regimens exist.
## Pediatric Dosing
* **GERD/Erosive Esophagitis (1 month to 16 years):**
* Oral: 1.25 mg/kg/day orally once daily, not to exceed 40 mg/day.
* IV: 1 mg/kg/day IV once daily, not to exceed 40 mg/day.
* **Note:** Dosing in neonates and infants may vary based on clinical judgment and requires careful monitoring. Consult specific pediatric guidelines.
## Dose Adjustments
* **Hepatic Impairment:** Reduce the dose of pantoprazole to 20 mg orally or 40 mg intravenously once daily.
## Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, flatulence, vomiting.
* Serious: *Clostridium difficile*-associated diarrhea, bone fracture (hip, wrist, spine) with prolonged use, hypomagnesemia (especially with concurrent diuretic use or >1 year of therapy), vitamin B12 deficiency, potential for lupus erythematosus.
## Key Drug Interactions
* **Antiretrovirals:** Drugs with pH-dependent absorption (e.g., atazanavir, nelfinavir) may have decreased absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May increase levels of drugs metabolized by this enzyme (e.g., clopidogrel, voriconazole).
* **Warfarin:** May increase INR and risk of bleeding. Monitor INR closely.
## Monitoring
* Monitor for signs and symptoms of *C. difficile* infection.
* Assess for bone fracture risk with long-term therapy.
* Monitor serum magnesium levels, especially with prolonged use or concurrent diuretic therapy.
* Monitor for signs and symptoms of vitamin B12 deficiency with prolonged therapy.
## Clinical Pearls
* Administer oral pantoprazole at least 30 minutes before a meal.
* IV pantoprazole should be infused over at least 15 minutes.
* Long-term PPI use is associated with increased risk of bone fractures, *C. difficile* infection, and hypomagnesemia. Consider the lowest effective dose for the shortest duration necessary.
* Discontinuation of PPIs should be tapered, not abrupt, to minimize rebound acid hypersecretion.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional judgment. Always consult the most current prescribing information and relevant clinical guidelines for complete details, including contraindications, warnings, and potential drug interactions, before making any treatment decisions.
